Biomerica, Inc. (BMRA) financial statements (2022 and earlier)

Company profile

Business Address 17571 VON KARMAN AVENUE
IRVINE, CA 92614
State of Incorp. DE
Fiscal Year End May 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

11/30/2021
Q2
8/31/2021
Q1
5/31/2021
Q4
2/28/2021
Q3
11/30/2020
Q2
8/31/2020
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,1994,9974,1995,2735,6846,964
Cash and cash equivalents7,1994,9974,1995,2735,6846,964
Receivables1,097291,4551,8781,6121,583
Inventory, net of allowances, customer advances and progress billings2,9822,8623,2062,8604,1984,101
Inventory2,9822,8623,2062,8604,1984,101
Other undisclosed current assets1,1251,058370774453471
Total current assets:12,4038,9469,23110,78511,94713,120
Noncurrent Assets
Operating lease, right-of-use asset1,4271,4901,5531,5381,5961,654
Property, plant and equipment274288311308288292
Intangible assets, net (including goodwill)389360295269218216
Intangible assets, net (excluding goodwill)389360295269218216
Other noncurrent assets150267264283262445
Other undisclosed noncurrent assets165165165165165165
Total noncurrent assets:2,4062,5702,5882,5632,5312,772
TOTAL ASSETS:14,80911,51611,81913,34814,47815,892
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,5816415837561,2581,271
Accounts payable  432   
Accrued liabilities  152   
Employee-related liabilities674508 367392309
Other undisclosed accounts payable and accrued liabilities906134 389866962
Other undisclosed current liabilities3,160841717596616531
Total current liabilities:4,7411,4821,3001,3521,8741,801
Noncurrent Liabilities
Long-term debt and lease obligation1,1671,2311,2921,3961,4551,510
Operating lease, liability1,1671,2311,2921,3961,4551,510
Other undisclosed noncurrent liabilities(1,167)(1,231)(1,292)(1,396)(1,455)(1,510)
Total noncurrent liabilities:1,1671,231 1,3961,4551,510
Total liabilities:5,9082,7132,5922,7483,3293,312
Stockholders' equity
Stockholders' equity attributable to parent8,9018,8039,22710,60011,14912,581
Preferred stock    2626
Common stock1,0151,001985984942940
Additional paid in capital41,15939,94538,83736,56435,28535,231
Accumulated other comprehensive loss(58)(54)(48)(49)(43)(42)
Accumulated deficit(33,214)(32,089)(30,546)(26,900)(25,060)(23,575)
Total stockholders' equity:8,9018,8039,22710,60011,14912,581
TOTAL LIABILITIES AND EQUITY:14,80911,51611,81913,34814,47815,892

Income statement (P&L) ($ in thousands)

11/30/2021
Q2
8/31/2021
Q1
5/31/2021
Q4
2/28/2021
Q3
11/30/2020
Q2
8/31/2020
Q1
Revenues4,6471,2621,0543,6291,3731,144
Cost of revenue(3,875)(1,351)(1,194)(3,667)(1,011)(961)
Gross profit:772(89)(140)(39)361183
Operating expenses(1,902)(1,451)(2,344)(1,842)(1,841)(1,839)
Operating loss:(1,130)(1,540)(2,483)(1,880)(1,480)(1,656)
Nonoperating income77133888
Investment income, nonoperating77133888
Interest and debt expense  (0)(0)  
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes  (0)0  
Loss from continuing operations before equity method investments, income taxes:(1,123)(1,534)(2,471)(1,842)(1,472)(1,648)
Other undisclosed income from continuing operations before income taxes  0   
Loss from continuing operations before income taxes:(1,123)(1,534)(2,471)(1,842)(1,472)(1,648)
Income tax expense (benefit)(2)(9)(2)3(13)(1)
Net loss available to common stockholders, diluted:(1,125)(1,543)(2,472)(1,839)(1,485)(1,649)

Comprehensive Income ($ in thousands)

11/30/2021
Q2
8/31/2021
Q1
5/31/2021
Q4
2/28/2021
Q3
11/30/2020
Q2
8/31/2020
Q1
Net loss:(1,125)(1,543)(2,472)(1,839)(1,485)(1,649)
Comprehensive loss:(1,125)(1,543)(2,472)(1,839)(1,485)(1,649)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(5)(6)1(5)(2)(2)
Comprehensive loss, net of tax, attributable to parent:(1,130)(1,548)(2,472)(1,845)(1,487)(1,651)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: